9 Meters Biopharma Inc (NMTR) Stock
NMTR is no longer traded. 9 Meters Biopharma was delisted from the Nasdaq in September 2023.
Prices on this page are historical; the last trade was September 26, 2023 at $0.02.
9 Meters Biopharma stock price history
NMTR final trading statistics
- Final close
- $0.02
- Final trading day
- Sep 26, 2023
- Market cap at delisting
- $1.04M
- Shares outstanding
- 14.46M
- Final 52-week range
- $0.01 – $5.20
- Avg. volume (final 3 mo.)
- 676,143
- All-time high (split-adj.)
- $1353.70 · Feb 2021
- All-time low (split-adj.)
- $0.01 · Aug 2023
- Return since IPO
- -100.0%
- Beta
- 1.48
- Book value / share
- -$0.44
- Price / book
- -0.05
9 Meters Biopharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$45.5M | -$3.24 |
| FY2021 | $0.00 | -$36.8M | -$3.00 |
| FY2020 | $0.00 | -$65.5M | -$2.84 |
| FY2019 | $0.00 | -$28.9M | -$11.29 |
| FY2018 | $0.00 | -$24.2M | -$4.67 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About 9 Meters Biopharma Inc
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
9 Meters Biopharma stock FAQ
What happened to 9 Meters Biopharma stock?
9 Meters Biopharma stock was delisted from the Nasdaq. Its final close was $0.02 on September 26, 2023.
Is NMTR stock still trading?
No. NMTR was delisted from the Nasdaq in September 2023 and no longer trades on a U.S. exchange.
What was the last price of NMTR stock?
NMTR closed at $0.02 on its final trading day, September 26, 2023, for a market value of about $1.04M.
What were 9 Meters Biopharma's revenue and earnings in its last full fiscal year?
9 Meters Biopharma reported revenue of $0.00 and net income of -$45.5M in fiscal 2022, its last full year as a public company.
When did 9 Meters Biopharma go public?
9 Meters Biopharma Inc stock began trading on July 8, 2016.